References
- Akasaka T, Tanaka M, Yamaguchi A, et al. Type II topoi-somerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother 2001; 45: 2263–2268.
- Lee JK, Lee YS, Park YK, et al. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 2005; 25: 290–295.
- Mouneimne H, Robert J, Jarlier V, et al. Type II topoiso-
- Nakano M, Deguchi T, Kawamura T, et al. Mutations in
- Takenouchi T, Sakagawa E, Sugawara M. Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones. Antimicrob Agents Chemother 1999; 43: 406–409.
- Kohler T, Michea-Hamzehpour M, Plesiat P, et al. Differ-ential selection of multidrug efflux systems by quinolones in
- Llanes C, Hocquet D, Vogne C, et al. Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously. Antimicrob Agents Chemother 2004; 48: 1797-1802.
- Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005; 56: 20-51.
- Cambau E, Perani E, Dib C, et al. Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem. Antimicrob Agents Chemother 1995; 39: 2248-2252.
- Oh H, Stenhoff J, Jalal S, et al. Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone- resistant Pseudomonas aeruginosa strains. Microb Drug Resist 2003; 9: 323-328.
- Bebear CM, Renaudin J, Charron A, et al. Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro. Antimicrob Agents Chemother 1998; 42: 2304-2311.
- Houssaye S, Gutmann L, Varon E. Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46: 2712-2715.
- Reinhardt AK, Bébéar CM, Kobisch M, et al. Characteri-zation of mutations in DNA gyrase and topoisomerase IV In-volved in quinolone resistance of Mycoplasma gallisepticum mu-tants obtained in vitro. Antimicrob Agents Chemother 2002; 46: 590–593.
- Lomovskaya 0, Warren MS, Lee A, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combina-tion therapy. Antimicrob Agents Chemother 2001; 45: 105-116.
- Kriengkauykiat J, Porter E, Lomovskaya 0, et al. Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resist-ance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 565–570.